Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Cerilliant
Deloitte
Moodys
Cipla
Fuji
Federal Trade Commission
Medtronic
Farmers Insurance

Generated: November 18, 2018

DrugPatentWatch Database Preview

King Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?

KING PHARMS has twenty-seven approved drugs.

There are six US patents protecting KING PHARMS drugs.

Summary for King Pharms
US Patents:6
Tradenames:25
Ingredients:23
NDAs:27

Drugs and US Patents for King Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms CYTOMEL liothyronine sodium TABLET;ORAL 010379-003 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 AB RX Yes No 7,368,469 ➤ Sign Up ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-002 May 25, 2001 AB1,AB3 RX Yes No 7,101,569 ➤ Sign Up ➤ Sign Up
King Pharms Llc BICILLIN L-A penicillin g benzathine INJECTABLE;INJECTION 050141-001 Approved Prior to Jan 1, 1982 BC RX Yes Yes ➤ Sign Up ➤ Sign Up
King Pharms CYTOMEL liothyronine sodium TABLET;ORAL 010379-002 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-008 May 25, 2001 AB1,AB3 RX Yes No 7,067,148 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for King Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc TILADE nedocromil sodium AEROSOL, METERED;INHALATION 019660-001 Dec 30, 1992 4,474,787 ➤ Sign Up
King Pharms Llc INTAL cromolyn sodium SOLUTION;INHALATION 018596-001 May 28, 1982 3,975,536 ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 4,587,258 ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 5,403,856 ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 5,061,722 ➤ Sign Up
King Pharms Llc CORZIDE bendroflumethiazide; nadolol TABLET;ORAL 018647-001 May 25, 1983 3,935,267 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for KING PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 30 mg, 60 mg, 90 mg and 120 mg ➤ Subscribe 2007-06-04
➤ Subscribe Tablets 800 mg ➤ Subscribe 2004-11-04
➤ Subscribe Extended-release Capsules 45 mg and 75 mg ➤ Subscribe 2009-07-30

Supplementary Protection Certificates for King Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/047 United Kingdom ➤ Sign Up PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
C0062 France ➤ Sign Up PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C0001 Belgium ➤ Sign Up PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
13/055 Ireland ➤ Sign Up PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
80030 Netherlands ➤ Sign Up PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
323 Luxembourg ➤ Sign Up PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
AstraZeneca
Chinese Patent Office
Cantor Fitzgerald
Fuji
Daiichi Sankyo
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.